Lapatinib Newbury

Lapatinib, the active ingredient in Lapatinib Newbury, is a tyrosine kinase inhibitor presented as an oral tablet of unspecified strength for oral administration. It belongs to the targeted therapy class and is indicated for the treatment of HER2‑positive metastatic breast cancer and HER2‑positive advanced gastric cancer in adult patients.

GNH USA supplies Lapatinib Newbury as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring quality‑assured product availability across regulated markets and adhering to stringent regulatory standards.

Lapatinib is a targeted therapy that inhibits HER2‑driven signaling pathways in certain cancers. - HER2‑positive metastatic breast cancer: when added to standard chemotherapy, Lapatinib has been shown to extend progression‑free survival and, in some studies, improve overall response rates in adult patients. - HER2‑positive advanced gastric cancer: Lapatinib is combined with chemotherapy agents to slow tumor growth, providing clinical benefit by prolonging time to disease progression in eligible patients. - HER2‑positive early breast cancer (adjuvant setting): investigated as part of combination therapy to reduce the risk of disease recurrence after surgery.

Lapatinib may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Diarrhea: frequent watery stools that may lead to dehydration. - Rash: acne‑like skin eruptions, often on the trunk and extremities. - Nausea: feeling of sickness that may be accompanied by vomiting. - Fatigue: persistent tiredness affecting daily activities. Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver failure requiring monitoring. - Cardiac dysfunction: decreased left ventricular ejection fraction or heart failure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating Lapatinib therapy, clinicians should consider several precautionary measures to ensure patient safety. - Cardiac monitoring: assess baseline and periodic left ventricular function during treatment. - Liver function: check hepatic enzymes before start and regularly while on therapy. - Skin assessment: examine for rash or severe dermatologic reactions and manage promptly. - Diarrhea management: educate patients on early intervention and hydration strategies. - Drug hypersensitivity: avoid use in individuals with known allergy to Lapatinib or its excipients. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Lapatinib is metabolized primarily by CYP3A4, and several drugs can alter its plasma concentrations. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lapatinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy by lowering drug levels. - Antacids that raise gastric pH (e.g., aluminum‑magnesium hydroxide): can decrease absorption of Lapatinib. Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., warfarin, tacrolimus): monitor plasma levels. - Statins (e.g., simvastatin, lovastatin): increased risk of myopathy; consider dose adjustment. - Oral contraceptives: Lapatinib may reduce effectiveness; advise alternative contraception.